New arrangements for migalastat (Galafold®) for treatment of Fabry Disease

This fact sheet is for current and future patients with Fabry disease explaining how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS. It provides further clarity on future access arrangements via the PBS.

New arrangements for migalastat (Galafold) – patient fact sheet

About this resource

Publication date:
Publication type:
Fact sheet
Audience:
General public
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.